Additional manufacturing capacity for BioNTech/Pfizer’s COVID-19 vaccine approved by the European Medicines Agency

Additional manufacturing and filling lines at Pfizer’s vaccine manufacturing site in Belgium has been approved by the EMA, which will significantly increase the volume of vaccines that can be produced at this site.

Source:

European Medicines Agency